Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
PDGFR inhibitor
DRUG CLASS:
PDGFR inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
imatinib (166)
sunitinib (139)
TKI258 (9)
MLN518 (8)
Max-40279 (2)
ABT-869 (2)
vorolanib (1)
CS 2164 (1)
squalamine (0)
pegpleranib (0)
R1530 (0)
ABT348 (0)
TSU-68 (0)
BAY 57- 9352 (0)
imatinib (166)
sunitinib (139)
TKI258 (9)
MLN518 (8)
Max-40279 (2)
ABT-869 (2)
vorolanib (1)
CS 2164 (1)
squalamine (0)
pegpleranib (0)
R1530 (0)
ABT348 (0)
TSU-68 (0)
BAY 57- 9352 (0)
›
Associations
(330)
News
Trials
Search handles
@AtishChoudhury
@DrCraigGedye
@DrDanielHeng
@Dr_R_Kurzrock
@JTrentMDPhD
@MosheOrnsteinMD
@PestanaRC
@StephenVLiu
@TalhaBadarMD
@jgong15
@neerajaiims
@schoffski
@smbenlazar
@teamoncology
Search handles
@AtishChoudhury
@DrCraigGedye
@DrDanielHeng
@Dr_R_Kurzrock
@JTrentMDPhD
@MosheOrnsteinMD
@PestanaRC
@StephenVLiu
@TalhaBadarMD
@jgong15
@neerajaiims
@schoffski
@smbenlazar
@teamoncology
Filter by
Latest
8ms
Lenvatinib plus pembrolizumab demonstrated improved ORR compared with sunitinib monotherapy in treatment-naïve patients with advanced RCC regardless of risk status or PD-L1 expression. @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/p1LcSl5Czk (@OncLive)
8 months ago
Clinical • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Lenvima (lenvatinib)
8ms
Comparing the cost-effectiveness of immunotherapy-based regimens and sunitinib in treating metastatic #RenalCellCarcinoma from a public payer perspective. Manish Kohli, MD @huntsmancancer joins @PBarataMD @caseccc to discuss on UroToday > https://t.co/pKTfVnZcwj @JCOOP_ASCO (@urotoday)
8 months ago
Clinical • HEOR • Cost effectiveness • Metastases
|
Sutent (sunitinib)
8ms
According to data from the final OS analysis of the CLEAR study, lenvatinib plus pembrolizumab produced an ORR of 71.3% in treatment-naïve patients with advanced RCC vs 36.7% with sunitinib. @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/NDvc1gD1Ne (@OncLive)
8 months ago
Clinical • Metastases
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Lenvima (lenvatinib)
9ms
- CML imatinib (& other rarer dz) - EGFR, ALK, ROS, & others in NSCLC - HER2 in breast, gastric Ca - BRAF/MEK in melanoma, thyroid & others - FLT3, IDH in AML (tho trial designs variable) - PSMA in Lu-PSMA @Dr_R_Kurzrock (@Eddie_Cliff)
9 months ago
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
|
imatinib
9ms
Frontline Lenvatinib Plus Pembrolizumab Produces Superior Responses Vs Sunitinib in Advanced RCC @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/RQML5zNQnC (@OncLive)
9 months ago
Metastases
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Lenvima (lenvatinib)
9ms
@DrChoueiri discussing SAMETA - p3 trial for savolitinib+durva vs sunitinib vs durva in pts with MET-driven papillary RCC @kidneycan #KCRS23 (@MosheOrnsteinMD)
9 months ago
Clinical
|
Sutent (sunitinib) • Orpathys (savolitinib)
9ms
S3: Trials In Progress ⚡️ SAMETA A Phase 3 Study of Savolitinib + Durva vs Sunitinib vs Durva Alone in Patients with MET-Driven Advanced Papillary RCC @DrChoueiri @DanaFarber_GU @kidneycan #KCRS23 (@MikeSerzanMD)
9 months ago
Clinical • P3 data • Metastases
|
Sutent (sunitinib) • Orpathys (savolitinib)
9ms
The combination of pembrolizumab + axitinib continued to improve OS, PFS, & ORR over sunitinib monotherapy in patients with treatment-naïve clear cell RCC. @brian_rini @VUMChealth #kcsm https://t.co/tKcszvDygl (@OncLive)
9 months ago
Clinical
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Inlyta (axitinib)
9ms
1. First in man study of gleevec in CML. 2. Discovery of EGFR mutations in patients who respond to gefitinib. 3. Whole genome sequencing of the first AML genome. (@rosslevinemd)
9 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
gefitinib • imatinib
9ms
Lenvatinib plus pembrolizumab showed a sustained overall survival and progression-free survival benefit vs sunitinib alone at a median follow-up of 4 years in patients with advanced renal cell carcinoma. @DrTHut @bswhealth https://t.co/2uj87xQ7pv (@OncLive)
9 months ago
Clinical • Metastases
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Lenvima (lenvatinib)
9ms
Lenvatinib plus pembrolizumab showed a sustained overall survival and progression-free survival benefit vs sunitinib alone at a median follow-up of 4 years in patients with advanced renal cell carcinoma. @DrTHut @bswhealth https://t.co/PJMI5i2fqE (@OncLive)
9 months ago
Clinical • Metastases
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Lenvima (lenvatinib)
9ms
The combination of pembrolizumab + axitinib continued to improve OS, PFS, & ORR over sunitinib monotherapy in patients with treatment-naïve clear cell RCC. @brian_rini @VUMChealth #kcsm https://t.co/YN4Oz9QJRP (@OncLive)
9 months ago
Clinical
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Inlyta (axitinib)
9ms
.@DrChoueiri and Rohit Gosain, MD, reviewed results from the phase 3 CheckMate 9ER trial which asseed nivolumab plus cabozantinib vs sunitinib in patients with renal cell carcinoma. #rccsm https://t.co/Sahrg8aNOy (@CancerNetwrk)
9 months ago
Clinical
|
Opdivo (nivolumab) • Sutent (sunitinib) • Cabometyx (cabozantinib tablet)
9ms
Eric A. Singer, MD, discusses the #FDA approval of adjuvant sunitinib and data that support the approval for patients with high-risk renal cell carcinoma. #RCC #kcsm | @eric_facs @OSUCCC_James https://t.co/qaR5uc0Poh (@TargetedOnc)
9 months ago
Clinical • FDA event
|
Sutent (sunitinib)
9ms
Exactly, often "not enough events occurred at time of data cut off for difference in OS to reach statistical significance" is reported as "no difference in OS". In GU, S-TRAC of adjuvant sunitinib in RCC clearly fits the definition in the slide, but others are more nuanced. (@AtishChoudhury)
9 months ago
Clinical
|
Sutent (sunitinib)
9ms
8/19 #TumorBoardTuesday #Sarcoma 👩🏻🏫Mini tweetorial 5👨🏻🏫 📰 Extra! Extra! 📰 ⬆️ TTP with sunitinib (SU) vs placebo 👍🏽 FDA approves SU for IM-resistant unresectable/adv #GIST 📚@DrSarcoma @CFletcherMD https://t.co/lspox5XwDG (@SteveBialickDO)
9 months ago
Clinical • FDA event
|
Sutent (sunitinib)
10ms
Comparing the cost-effectiveness of immunotherapy-based regimens and sunitinib in treating metastatic #RenalCellCarcinoma from a public payer perspective. Manish Kohli, MD @huntsmancancer joins @PBarataMD @caseccc to discuss on UroToday > https://t.co/pKTfVnYEGL @JCOOP_ASCO (@urotoday)
10 months ago
Clinical • HEOR • Cost effectiveness • Metastases
|
Sutent (sunitinib)
10ms
At #ASCO23, @WallisCJD interviewed @brian_rini on an abstract focused on KEYNOTE-426, which revealed long-term survival data on pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell #RCC. Watch now: https://t.co/mUQplYnsxo (@GUOncologyNow)
10 months ago
Clinical • Interview • Metastases
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Inlyta (axitinib)
10ms
3-year follow-up #CheckMate9ER trial: Nivolumab + cabozantinib vs sunitinib for first-line treatment of advanced #RenalCellCarcinoma. @BurottoMauricio @bradfordhill_cl joins @PBarataMD @caseccc to discuss on UroToday > https://t.co/fAh3th9BZQ @ExelixisInc @CABOMETYX (@urotoday)
10 months ago
Clinical • Metastases
|
Opdivo (nivolumab) • Sutent (sunitinib) • Cabometyx (cabozantinib tablet)
10ms
According to data presented at #ASCO2023 by @brian_rini, pembrolizumab plus axitinib continued to confer a survival benefit over sunitinib at 5-year follow-up as first-line therapy among certain patients with renal cell carcinoma. @VUMChealth https://t.co/2iKpCva6Ks (@HemOncToday)
10 months ago
Clinical
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Inlyta (axitinib)
10ms
Rana R. McKay, MD, and Brian I. Rini, MD, on Clear Cell RCC: New Data From KEYNOTE-426 on Pembrolizumab Plus Axitinib vs Sunitinib https://t.co/OYVw3Hb8Vv #kcsm #kidneycancer #RCC #oncology #ASCO23 @DrRanaMcKay @UCSanDiego @brian_rini (@ASCOPost)
10 months ago
Keytruda (pembrolizumab) • Sutent (sunitinib) • Inlyta (axitinib)
10ms
Not true, when Mark’s company first started he always talked about a leukemia drugs for kids called Imatinib that’s available through the pharmacy. It’s a chemotherapy. Its retail value at the time was like $2500 and available through this company for $20 (@David97903896)
10 months ago
imatinib
10ms
They have Imatinib, a leukemia chemotherapy. Not sure why they wouldn’t carry others (@David97903896)
10 months ago
imatinib
10ms
Elias Jabbour: Presented PhALLCON study data, higher MRD neg CR with ponatinib. Better PFS, no difference in OS (albeit shorter fu, cross over; imatinib pt receiving 2/3rd generation TKI on relapse). G3/4 AEs were comparable. #EHA2023 #EHA23 #leusm (@TalhaBadarMD)
10 months ago
imatinib • Iclusig (ponatinib)
10ms
Elias Jabbour: Presented PhALLCON study data, higher MRD neg CR with ponatinib. Better PFS, no difference in OS (albeit shorter fu and imatinib pt receiving 2/3rd generation TKI on relapse). G3/4 AEs were comparable. #EHA2023 #EHA23 #leusm (@TalhaBadarMD)
10 months ago
imatinib • Iclusig (ponatinib)
10ms
HOPES in Gist. Si somos capaces de detectar mutaciones de resistencia a imatinib y desarrollar farmacos dirigidos que las reviertan podremos impactar en la supervivencia de los pacientes. #GIST @DrCeSarcoma @colectivogist (@GrupoGeis)
10 months ago
imatinib
10ms
@BraunMDPhD did a masterful job highlighting how far we have come – starting with the cytokine era in the 80's to the combination era today. Since the approval of sunitinib in 2006 – the median overall survival for kidney cancer has more than doubled. That is news to celebrate. (@RCCadvocate)
10 months ago
Clinical
|
Sutent (sunitinib)
10ms
Updated 5y Analysis of Pembrolizumab +Axitinib vs Sunitinib? ➡️KEYNOTE426: Ph3 trial ✔️Longest fu to date of combination IO-TKI 1L mRCC ✔️Pem+Axit: Continued OS, PFS, ORR >sunitinib @brian_rini @ASCO @OncoAlert #ASCO23 #mRCC (@jordanciuro)
10 months ago
Keytruda (pembrolizumab) • Sutent (sunitinib) • Inlyta (axitinib)
10ms
Final prespecified overall survival analysis of #CLEAR: 4-year follow-up of lenvatinib + pembrolizumab vs sunitinib in patients with advanced #RCC. Presented by @DrTHut @TexasOncology. #ASCO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/iNmENLYSYe @ASCO (@urotoday)
10 months ago
Clinical • Metastases
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Lenvima (lenvatinib)
10ms
@DrTHut 4-yr F/U of PhIII CLEAR len+pembro in #1L adv ccRCC adjusted OS benefit over sunitinib maintained w/71.3% ORR (CR 18.3%) vs 36.7% (CR 5%), depth of response was prognostic of OS. DOR median 26.7 w/combo vs 14.7 mos w/sunitinib #ASCO23 @OncoAlert (@jgong15)
10 months ago
Keytruda (pembrolizumab) • Sutent (sunitinib) • Lenvima (lenvatinib)
10ms
Thomas E. Hutson, DO, PharmD, on RCC: Overall Survival Analysis of Lenvatinib, Pembrolizumab, and Sunitinib https://t.co/Gc52zEdQLJ #kcsm #kidneycancer #RCC #oncology #ASCO23 @DrTHut @TexasOncology (@ASCOPost)
10 months ago
Clinical
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Lenvima (lenvatinib)
10ms
Pembro+axi vs sunitinib update presented by @brian_rini. Seems to be a PFS tail of the curve of 18% at 5 years. We cannot compare across trials like CM214 but there are indeed long term duration of response patients. @oncoalert @pfizer @Merck @VanderbiltU #kidneycancer @IKCCorg (@DrDanielHeng)
10 months ago
Clinical
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Inlyta (axitinib)
10ms
Dr. Andrew Johns discussed findings from a Phase II study of cabozantinib versus sunitinib for non-clear cell renal cell carcinoma (abstract 4597). https://t.co/feBavKiCcn @andrewjohnsmd @PavlosMsaouel @ASCO #ASCO23 #KidneyCancer #BladderCancer #EndCancer (4/9) (@MDAndersonNews)
10 months ago
Sutent (sunitinib) • Cabometyx (cabozantinib tablet)
10ms
A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia https://t.co/0MJllt15hd #CML #scRNAseq @BloodJournal (@TalhaBadarMD)
10 months ago
imatinib
10ms
https://t.co/1taZrhA1gA: Treatment failure with first line imatinib for patients with chronic myeloid leukaemia in Kenya vs high-income countries. ➡️ Imatinib failure rate 15% #ASCO23 (@TalhaBadarMD)
10 months ago
Clinical
|
imatinib
10ms
Abs#4527 #ASCO23 @ASCO : The CheckMate 9ER trial of nivolumab + cabozantinib (NIVO+CABO) vs sunitinib (SUN) for advanced #kidneycancer ➡️ Compared with SUN, NIVO+CABO ⬆️ or maintained HRQoL in I/P-risk pts and had less side effect in all subgroups. @DrChoueiri @sm_blum… https://t.co/3wlVSmJFnm (@neerajaiims)
10 months ago
Clinical • Adverse events • Metastases
|
Opdivo (nivolumab) • Sutent (sunitinib) • Cabometyx (cabozantinib tablet)
10ms
Ab#4502 #ASCO23 @ASCO : Final OS analysis of CLEAR ph 3 trial of lenvatinib + pembrolizumab (L + P) vs sunitinib in 1st line mRCC #kidneycancer ➡️ L + P continues to improve OS, PFS, ORR, and CR at 4-yr follow-up 👉 https://t.co/9Q5WLnQLvD @DrChoueiri @motzermd @tompowles1… https://t.co/L7g1XchoD0 (@neerajaiims)
10 months ago
Keytruda (pembrolizumab) • Sutent (sunitinib) • Lenvima (lenvatinib)
10ms
3-year follow-up #CheckMate9ER trial: Nivolumab + cabozantinib vs sunitinib for first-line treatment of advanced #RenalCellCarcinoma. @BurottoMauricio @bradfordhill_cl joins @PBarataMD @caseccc to discuss on UroToday > https://t.co/fAh3th9BZQ @ExelixisInc @CABOMETYX (@urotoday)
10 months ago
Clinical • Metastases
|
Opdivo (nivolumab) • Sutent (sunitinib) • Cabometyx (cabozantinib tablet)
11ms
PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL .... by Dr. Elias Jabbour EHA Library; Jun 08 2023; 387810 https://t.co/OH6yo7ci3P #ALL #EHA23 (@smbenlazar)
11 months ago
imatinib • Iclusig (ponatinib)
11ms
PHALLCON study: Ponatanib vs imatinib with low intensity chemotherapy in Ph positive ALL: significantly better molecular MRD -ve CR with ponatinib and trends towards better EFS. #EHA23 #leusm (@TalhaBadarMD)
11 months ago
Minimal residual disease
|
imatinib • Iclusig (ponatinib)
11ms
These arguments just don't make sense. Sunitinib is marketed by Pfizer, all the other drugs approved in RCC by Merck/BMS/Exelixis. Same with sorafenib (bayer) and avastin+atezo (Roche). The fact that old SoC is off patent is worse for the newcomers, as it means price is a factor (@Ivaj960612)
11 months ago
Avastin (bevacizumab) • sorafenib • Sutent (sunitinib)
11ms
•KIT/PDGFRA mutations in metastatic, imatinib-resistant #GIST •Prior Tx selects for resistant A-loop mutations •ctDNA resistance mutations prognosticate efficacy of 3rd/4th-line TKI @Annals_Oncology @DrCeSarcoma @SteveBialickDO @seppobauer S. George https://t.co/Mgzutsu317 (@JTrentMDPhD)
11 months ago
Clinical • Circulating tumor DNA • Metastases
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
|
KIT mutation • PDGFRA mutation
|
imatinib
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login